Equities

Genus PLC

GNS:LSE

Genus PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)3,035.00
  • Today's Change5.00 / 0.17%
  • Shares traded66.48k
  • 1 Year change67.31%
  • Beta1.3908
Data delayed at least 20 minutes, as of Feb 06 2026 16:35 GMT.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Feb-25
  • 20-Nov-25
  • 18-Dec-25
  • 15-Jan-26
  • 05-Feb-26
Select bar for recommendation details.
Recommendations05-Feb-26
Buy4
Outperform4
Hold1
Sell0
Strong Sell0

Share price forecast

The 9 analysts offering 12 month price targets for Genus plc have a median target of 3,200.00, with a high estimate of 3,500.00 and a low estimate of 2,550.00. The median estimate represents a 5.44% increase from the last price of 3,035.00.
High15.3%3,500.00
Med5.4%3,200.00
Low-16.0%2,550.00

Dividends

In 2025, Genus PLC reported a dividend of 0.32 GBP, equaling last years dividend. The 10 analysts covering the company expect dividends of 0.33 GBP for the upcoming fiscal year, an increase of 3.44%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates

Genus plc reported annual 2025 earnings of 80.60 per share on Sep 04, 2025.
Average growth rate-3.57%
More ▼

Revenue history & estimates

Genus plc had revenues for the full year 2025 of 672.80m. This was 0.60% above the prior year's results.
Average growth rate+4.28%
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.